Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab

INTRODUCTION: Immune checkpoint inhibitors (CPIs) have changed the treatment landscape for many cancers, but also cause severe inflammatory side effects including enterocolitis. CPI-induced enterocolitis is treated empirically with corticosteroids, and infliximab (IFX) is used in corticosteroid-refr...

Descripción completa

Detalles Bibliográficos
Autores principales: Alexander, James L, Ibraheim, Hajir, Sheth, Bhavisha, Little, Jessica, Khan, Muhammad Saheb, Richards, Camellia, Hunter, Nikki, Chauhan, Dharmisha, Ratnakumaran, Raguprakash, McHugh, Kathleen, Pinato, David J, Nathan, Paul, Choy, Julia, Crusz, Shanthini M, Furness, Andrew, Turajlic, Samra, Pickering, Lisa, Larkin, James, Teare, Julian P, Papa, Sophie, Speight, Ally, Sharma, Anand, Powell, Nick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264884/
https://www.ncbi.nlm.nih.gov/pubmed/34233964
http://dx.doi.org/10.1136/jitc-2021-002742

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264884/
https://www.ncbi.nlm.nih.gov/pubmed/34233964
http://dx.doi.org/10.1136/jitc-2021-002742

Ejemplares similares